Destination: Cure

Mosaic Design APPROACH, a preventive vaccine study, seeks to address more than one clade by Jeannie Wraight Over the past thirty-plus years, strategies such as Treatment as...

Risk & Reward Activist David Evans weighs in on next steps in cure advocacy & research by Jeannie Wraight In the late 1980s and throughout the ’90s,...

Luis J. Montaner DVM, D.Phil, of the Wistar Institute in Philadelphia, Pennsylvania has been studying the effects of interferon on HIV DNA and its...

BIT225 is a new type of antiviral called a Vpu inhibitor, which researchers are investigating to treat both HIV and HIV/hepatitis C (HCV) co-infection....

Buyer Beware The new administration may threaten HIV care and cure research by Jeannie Wraight Our way of life in the U.S. has already drastically changed as...

Step Forward Vaccine candidates like HTVN 702 are needed to build momentum by Jeannie Wraight If current HIV diagnoses rates persist, about 1 in 2 black men...

Another Road Broadly neutralizing antibodies aim for a diverse effect against HIV types by Jeannie Wraight and David Miller Broadly neutralizing antibodies (bNAbs) hold the potential of...

Everyone Counts Differences in intravenous drug users may affect their response to an HIV vaccine by Jeannie Wraight Prevention strategies such as Treatment as Prevention, PrEP, syringe...

LifeGuide It's a Man's World Research on women & PrEP needs to keep pace by Jeannie Wraight   Whereas HIV cure and HIV prevention are two very different...

Destination: Cure by Jeannie Wraight Counting Cures Before we start tallying “cures,” let’s strive to define what we mean by “cured?” Several months ago a media frenzy...